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There is mounting evidence that many highly processed foods have addictive properties,
and that some cases of compulsive overeating resemble an addiction disorder. While
support for the Yale Food Addiction Scale (YFAS) as a valid diagnostic tool has been
impressive and continues to increase, to date, no research has examined the food-addiction
construct in response to an actual food stimulus, and in relation to direct measures of
appetite and food consumption. As part of a larger community-based study of overeating
in healthy adults who were predominately overweight and obese (aged 25–50 years),
136 participants completed the YFAS, of whom 23 met the diagnostic criteria for food-
addiction. They took part in a 2-day, double-blind, cross-over, single-dose drug challenge
using a psychomotor stimulant (methylphenidate) and placebo. Participants were ﬁrst
assessed on ratings of appetite and food cravings after holding and tasting their favorite
snack food, after which they were able to eat all or part of the snack, as they wished.
Three separate repeated-measures analysis-of-variance procedures were carried out, each
with two between-subjects factors (Diagnosis: food-addiction vs. non-food addiction)
and (Sex: male vs. female) and 1 within-subjects factor (Days: drug vs. placebo). As
anticipated, for all three dependent variables, there was a signiﬁcant main effect for
Days with a response decrease from placebo to the drug condition. With respect to
food cravings and appetite ratings, results indicated that the food addiction group had
signiﬁcantly higher scores on both variables. For food consumption, there was a signiﬁcant
Days × Diagnosis interaction whereby the food-addiction group showed no food-intake
suppression across days compared to the non-food-addiction group who demonstrated
a signiﬁcant decrease in snack-food consumption with methylphenidate. The ﬁnding that
the food-addiction group was resistant to the food-intake suppression typically induced
by a dopamine agonist supports evidence of dopamine signaling-strength differences
in individuals with compulsive overeating compared to those without this disorder. This
represents the ﬁrst demonstration that individuals deﬁned by their food-addiction status
have a unique pattern of food-intake following a pharmacologic challenge with such
agents.
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INTRODUCTION
In its recently released 5th edition, the Diagnostic and Statisti-
cal Manual of Mental Disorders (DSM-5) has acknowledged the
existence of behavioral addictions for the ﬁrst time (American
Psychiatric Association, 2013). Currently, however, pathological
gambling is the only one listed in the newly labeled “non-
substance-related disorders” category. Although other excessive
behaviors related to sex, exercise, eating, and shopping had been
considered for inclusion, none was deemed to have sufﬁcient peer-
reviewed evidence for identiﬁcation as a mental health problem
at the time of publication (Potenza, 2014). Of these conditions,
the one receiving the most discussion and research investiga-
tion in recent years is food addiction – the rather unsuitably
named1 syndromedescribing compulsive overeating accompanied
by strong cravings and extreme difﬁculty in abstaining fromhighly
palatable fare. To illustrate, a keywords search in Web of Science
(an online scientiﬁc citation indexing service) for the year 2013 –
1There has been justiﬁed criticism of the contiguousness of the words “food” and
“addiction” in this putative diagnostic label because the word “food” connotes sub-
stances essential for survival and fundamental to human existence, while“addiction”
implies psychopathology and even antisocial behavior. More appropriate perhaps
would be terms like “hyper-palatable processed food” or “high fat, sweet, and salty
food” because those that are intensely craved and over-consumed, and that com-
prise most binge episodes are not grown or raised in nature. Instead they are highly
processed foods, calorically dense in fat, sugar, and salt, and are almost universally
perceived as very appetizing (Curtis and Davis, 2014).
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using the terms “food addiction,” “sex addiction,” and “shopping
addiction,” consecutively – rendered 48, 8, and 0 citations, in that
order.
The growing legitimacy of the food-addiction concept has
been heavily inﬂuenced by the premise that hyper-palatable foods,
rich in sugar, fat, and salt, have the potential to foster exces-
sive consumption and a state of dependence (Gearhardt et al.,
2011a; Davis and Carter, 2014), and that some cases of compulsive
overeating have striking clinical and neurophysiologic similar-
ities to drugaddiction (Davis and Carter, 2009; Davis, 2013).
Compelling preclinical research laid the groundwork and a solid
foundation of evidence for biobehavioral parallels between the
excessive consumption of sugar and fat and that of addictive drugs
like cocaine and heroin. Readers are referred to several excellent
reviews of this body of research (Avena et al., 2008, 2012; Cor-
win et al., 2011). The systematic study of clinical cases of food
addiction came somewhat later, but has increased rapidly. This
work began to ﬂourish with the development of the Yale Food
Addiction Scale (YFAS; Gearhardt et al., 2009) – a diagnostic tool
based on the seven DSM-IV (American Psychiatric Association,
1994) symptom criteria for substance dependence, with the word
“food” substituting for drugs in the questionnaire items. To date,
studies have found substantial co-morbidity between binge eating
disorder (BED) and YFAS food addiction, in addition to many
shared psychological and biological risk factors (Davis et al., 2011;
Gearhardt et al., 2011b, 2012). An even greater overlap was found
in an earlier study of women diagnosed with BED where 92%
of the sample met the DSM-IV criteria for dependence during a
structured telephone interview – again when food replaced the
drug/substance nomenclature in the assessment questions (Cassin
and von Ranson, 2007). A recent qualitative study also conﬁrmed
that a high proportion of obese women with and without BED
endorsed DSM symptoms of substance dependence when food
was the “substance” in question (Curtis and Davis, 2014). These
women felt that “loss-of-control” overeating, the inability to stop
this behavior despite strong wishes to do so, and extreme cravings
were the characteristics of their disorder whichmost resembled an
addiction.
The ﬁrst case-control study of food addiction in obese men
and women found that those who met the YFAS diagnostic cri-
teria had a signiﬁcantly greater prevalence of BED than their
age- and weight-matched counterparts (Davis et al., 2011). They
also reported more intense trait-related food cravings and greater
emotional and hedonic overeating than the control participants.
Other research has found similar results using the YFAS symp-
tom score (Meule et al., 2012). In addition, preliminary genetic
evidence demonstrated that a composite polymorphic index of
elevated dopamine signaling strength was greater in those who
met the YFAS criteria for food addiction, and this proﬁle score
correlated positively with binge eating severity, food cravings,
and emotional eating (Davis et al., 2013). Together these results
support the view that risk for food addiction is greater in
those with a hyper-sensitivity to reward and a greater appeti-
tive motivation for reinforcing stimuli. In a study of weight-loss
treatment-seeking adults, YFAS-symptom scores were also asso-
ciated with lower weight loss after several weeks of treatment,
suggesting that food addiction, with related signs of tolerance
and withdrawal, may undermine efforts to lose weight in those
trying to adopt better eating habits (Burmeister et al., 2013). A
later study, however, failed to replicate these results (Lent et al.,
2014).
In a recent general-population study, adults who met the YFAS
criteria for food addiction had signiﬁcantly higher body mass
index (BMIs) and a greater percentage of adipose tissue com-
pared to their non-food-addicted counterparts (Pedram et al.,
2013). They also self-reported eating more calories from fat and
protein. In addition, it was found that overweight and obese
women had a signiﬁcantly higher prevalence of food addiction
than weight-matched men. Interestingly, this sex bias reﬂects
the pattern of ﬁndings from drug-addiction research. For exam-
ple, while drug abuse has traditionally been more widespread
in men than in women (Wittchen et al., 2011), the gap seems
to be narrowing, suggesting that earlier differences may simply
reﬂect variation in opportunity and gender-biased expectations
rather than in vulnerability (Becker, 2009; Colell et al., 2013).
Indeed, it appears that many addiction risk factors are greater
in women than in men. Women tend to increase their rate of
drug consumption more quickly than men, are more likely to
relapse, and to have longer periods of drug use before their
next attempt at abstinence (Elman et al., 2001; Evans and Foltin,
2010) – a phenomenon known as telescoping, which describes
an accelerated progression from the commencement of drug
use to the development of dependence and admission to treat-
ment (Greenﬁeld et al., 2010). Women who abuse drugs also
report more severe cravings and subjective drug effects than their
male counterparts (Back et al., 2011), and this pattern seems
to be similar for most addictive substances (Becker and Ming,
2008).
There is now compelling evidence that the cravings for addic-
tive drugs and for hyper-palatable foods are fostered by similar
biological mechanisms whereby excessive consumption of either
provokes neuro-adaptations resulting in a blunted dopamine sig-
nal in brain reward circuitry – in particular, the nucleus accumbens
and the ventral tegmental area (VTA; Volkow et al., 2013). Exces-
sive consumption also contributes to a heightened motivational
salience for the reward, which, together with dopamine down-
regulation, increases the “wanting,” or an intense craving, for the
substance in question (Robinson and Berridge, 2013). Cravings
are therefore an important component of the addiction process,
especially because they appear to increase the risk for relapse
following abstinence (Sinha et al., 2006). In this context, it is note-
worthy that conventional weight-loss programs, including dietary
restriction and increased physical activity, are typically ineffec-
tive in the long term for patients with problematic overeating and
obesity (Begin et al., 2006; Mann et al., 2007). Indeed, numer-
ous obesity studies have linked cravings to overeating and weight
gain, to the lack of success in attempts to restrict calories, and
to early drop-out from bariatric treatment programs (Batra et al.,
2013).
Not surprisingly, given the down-regulatory neurophysio-
logic processes in addiction, treatments that serve to increase
dopamine signaling have shown some success in reducing
episodes of overeating. For example, in a randomized-control
trial, pharmacotherapy with an amphetamine-based stimulant
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medication was effective in lowering the frequency of binge
episodes in those with compulsive overeating (Shaffer, 2012;
Gasior et al., 2013). Similar medications have also been success-
ful in producing weight loss in those with intractable obesity
and co-morbid symptoms of attention deﬁcit/hyperactivity dis-
order (ADHD; Levy et al., 2009). Likewise, laboratory studies
of single-dose administrations of methylphenidate [a dopamine
transporter (DAT) blocker] have also shown decreased food crav-
ings and food consumption in obese adults and those with
BED (Leddy et al., 2004; Goldﬁeld et al., 2007; Davis et al.,
2012). And ﬁnally, non-invasive dorsolateral prefrontal corti-
cal (DLPFC) neurostimulation – a procedure which is believed
to increase dopamine excretion via interconnections between
the DLPFC and the VTA and nucleus accumbens – has also
produced reductions in drug and food cravings (Jansen et al.,
2013).
THE PRESENT STUDY
Although various studies have used food-related cues in their
experimental paradigms (Gearhardt et al., 2011b; Meule et al.,
2012), to the best of our knowledge, there are no objective
food consumption studies in human food-addiction research.
Since self-report measures of food intake may be subject to
biased recall, it is also important to have objective food-intake
data for a more complete understanding of the phenomenol-
ogy of disordered (and other) eating behaviors. The purpose of
the current study was therefore to compare appetite, cravings,
and consumption between adults diagnosed with and without
YFAS food addiction, in response to a snack-food challenge fol-
lowing a single-dose administration of methylphenidate versus
placebo. Given the generally experienced, appetite-suppression,
effects of stimulant drugs, and their suggested therapeutic use
in reducing binge episodes (Levy et al., 2009; Shaffer, 2012;
Gasior et al., 2013), the primary purpose for including the drug
challenge in the study protocol was to identify possible fac-
tors moderating response magnitude to methylphenidate, given
the considerable response variability among patients taking such
medications2.
Sex differences were also assessed in this 3-way mixed model,
double-blind, cross-over design. It was anticipated that the
food-addiction group would report greater appetite and food
cravings and consume more of their favorite snack during the
placebo condition than the non-food-addiction group. Another
goal of this study was to investigate whether food addic-
tion moderated the appetite-suppression effects typically found
following administration of methylphenidate. It was specu-
lated that the stronger appetitive responses to food associated
with food-addiction (Davis et al., 2013) might buffer the nor-
mally experienced suppression effect from methylphenidate.
Finally, and based on other sex differences in clinical and
pre-clinical drug-response research, it was predicted that
females would be more responsive to the appetite and food
consumption suppression effects of methylphenidate than
males.
2These potential moderators included genetic factors, results for which will be
published elsewhere for the larger study.
MATERIALS AND METHODS
PARTICIPANTS
As part of a larger community-based study of overeating in healthy
adults whowere predominately overweight and obese and between
the ages of 25 and 50 years, 136 participants (women = 92;
male = 44) completed the YFAS, of whom 23 met the diagnos-
tic criteria for food addiction. The food-addiction group had a
mean BMI of 34.6 ± 7.0 and a mean age of 33.9 ± 5.9 years
compared to the non-food-addiction group with a mean BMI of
33.8 ± 8.4 and a mean age of 32.4 ± 6.6 years. These values
were not signiﬁcantly different. Participants were recruited from
posters, newspaper advertisements, and online sites like Craigslist
and Kijiji. Inclusion criteria were residence in North America
for at least 5 years and ﬂuency in written and spoken English.
Women were also required to be pre-menopausal as indicated by
the reporting of regular menstrual-cycles. Exclusion criteria were
a current diagnosis (or history) of any psychotic disorder, panic
disorder, or substance abuse as diagnosed by the Structured Clin-
ical Interview for DSM-IV (SCID), any serious medical condition
like cancer, or heart disease, and any medications contraindicated
formethylphenidate (e.g., certain antidepressants likeWellbutrin).
Twenty-six percent of the food-addiction group, and 20 percent
of the control group were regular smokers. Women who were
pregnant or breast-feeding, or who had given birth within the past
6months were also excluded. This studywas approved by the insti-
tutional Research Ethics Boards and was carried out in accordance
with the Declaration of Helsinki.
MEASURES
Food addiction
Food addiction was diagnosed by the 25-item YFAS (Gearhardt
et al., 2009) – a self-report questionnaire measure – using the
dichotomous scoring procedure proposed by its authors. Based
on the DSM-IV (American Psychiatric Association, 1994) criteria
for substance dependence, a diagnosis is given if the respon-
dent endorses three or more of the symptom subscales “over
the past year” and if s/he also conﬁrms the “clinically signiﬁcant
impairment” criterion.
Food cravings
Food cravings were assessed by the 15-item State version of the
General Food Cravings Questionnaire (Cepeda-Benito et al., 2000).
This well-validated scale (Nijs et al., 2007) was personalized for
each participant by replacing the general words “tasty food” with
the speciﬁc snack-food each participant had identiﬁed. For exam-
ple, where appropriate, item one was changed from “I’m craving
tasty food” to “I’m craving potato chips,” and so on. The alpha
coefﬁcients for Day 1 and Day 2 were 0.93 and 0.92, respectively.
Appetite ratings
Appetite ratings were assessed, after participants had been given
their snack, by the sum of 3 Likert-scale questions, each scored
from 1 (“not at all”) to 10 (“a great deal”): (1) How hungry does
it make you feel to see your favorite snack? (2) How much would
you like to eat some of your favorite snack – even just a small
portion? (3) Now that you’ve had a taste of your favorite snack,
how strong is your desire to have some more? After the second
www.frontiersin.org May 2014 | Volume 5 | Article 403 | 3
Davis et al. Cravings, appetite, consumption, stimulant drugs
question, participants were asked to take a few bites of their snack,
before the third question was asked.
Snack-food consumption
Snack-food consumptionwas quantiﬁed as the weight of the snack
(to the nearest gram) at the end of the session subtracted from
the initial weight of the snack. The amount consumed was then
converted to a percentage of the initial snack weight. For example,
a score of zero indicated that none of the snack was eaten and a
score of 100 indicated the entire snack was eaten.
PROCEDURES
The data reported in this study are part of a larger and more
extensive protocol involving three separate assessment sessions.
They comprise a sub-set of participants who were assessed on the
YFAS. Using a randomized, double-blind, cross-over design, par-
ticipants were administered either a dose of oral methylphenidate
equivalent to 0.5 mg/kg body weight (to a maximum dose of
55 mg), or placebo, at the same time of day and the same day
of the week, separated by 1 week. This dose was selected because
it has been used successfully in other drug challenges with healthy
adults (Volkow et al., 2001). Methylphenidate was titrated for BMI
because of evidence-based recommendations that this compound
should be prescribed on a weight-adjusted basis (Shader et al.,
1999). Methylphenidate and placebo were packaged in identi-
cal colored capsules to prevent detection of the drug by taste or
color.
Day 1
Demographic information was obtained, a psychiatric assessment
was administered, and questionnaire measures were distributed
to be completed at home and returned at the second assessment.
Participants had height and weight measured, blood pressure was
taken, and an electrocardiogram was carried out to conﬁrm eli-
gibility for the subsequent drug challenge sessions. Participants
were also asked to indicate their “favorite snack food” in prepara-
tion for the food challenge taking place at the 2nd and 3rd session.
The most commonly chosen snacks were potato chips, chocolate
bars, and cookies. For a more detailed explanation of the protocol
see Davis et al. (2012).
Days 2 and 3
Both 2.5-h sessions were scheduled at the same time of day and
the same day of the week, separated by 1 week. Prior to each
session, participants were told to eat a normal meal 2 h before
their appointment and to abstain from drinking any caffeinated
beverage or smoking nicotine on the day of, and prior to, their
appointments. These dietary restrictions were conﬁrmed on each
testing day. Upon arrival at the laboratory, a 10-item, visual-
analog, mood adjective scale was given at baseline and every
15 min after the ingestion of the capsule. The peak uptake for
methylphenidate is approximately 1 h. During that time, par-
ticipants were seated in a quiet area and encouraged to occupy
themselves with reading materials. About an hour and 15 min
after the ingestion of the capsule, participants were given their
favorite snack-food to hold, and the appetite rating questions
were asked, after which they were given the craving question-
naire to complete. Participants were then told that the study tasks
were ﬁnished and they could eat as much of their snack as they
wished. At this point more than 3 h had elapsed since their last
meal.
RESULTS
In order to assesswhether therewere groupdifferences in the initial
weight of the snack food – since each participant chose his/her own
– a 2 (Sex) × 2 (Diagnostic Group) analysis of variance (ANOVA)
was carried out. Results conﬁrmed there were no differences
between men and women (p = 0.828) or between the food-
addiction and the non-food-addiction groups (p = 0.413), and
there was no signiﬁcant interaction between these two variables
(p = 0.974).
REPEATED MEASURES ANOVA
Three separate 2 × 2 × 2 mixed model, repeated measures
ANOVAs were computed – one for each of the dependent vari-
ables: food cravings, appetite ratings, and percentage of food
consumed. There was one within-subjects factor (Days: placebo
vs. drug) and two between-subjects factors: (Sex: male vs.
female) and (Diagnostic Group: food-addiction vs. non-food-
addiction)3.
With food cravings and appetite ratings as the dependent vari-
ables, there was a signiﬁcant main effect for Diagnostic Group
(p< 0.0001 for both: η2p = 0.157 and 0.128, respectively) with the
food-addiction group reporting higher scores than the non-food-
addiction group. In both cases, there was also a signiﬁcant main
effect for Days, indicating a diminution in scores in the drug con-
dition compared to the placebo condition (p = 0.006 and 0.031,
and η2p = 0.056 and 0.035, respectively), but these decreases on the
drug day were not signiﬁcantly different between those with and
without food addiction. These results are presented graphically in
Figures 1 and 2.
3Each of the three repeated measures ANOVAs was re-run with BMI included as
a co-variate. In each case, BMI did not correlate with the dependent variable nor
were the Days × BMI interaction terms statistically signiﬁcant, indicating that BMI
did not contribute to the variance in the appetite, cravings, and food-consumptions
variables. Therefore it was removed from the models. The values reported in the
Table and the Figures are the results without BMI.
FIGURE 1 | Plot for the Diagnostic Group × Days interaction with food
cravings as the dependent variable.
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FIGURE 2 | Plot for the Diagnostic Group × Days interaction with
appetite ratings as the dependent variable.
In conformance with statistical convention, the absence of a
signiﬁcant interaction between the food-addiction and non-food-
addiction variable and the placebo vs. drug variable precludes
the legitimate testing of post hoc individual-Group comparisons
across Days. It is important to note, however, that this interac-
tion is testing the signiﬁcance of the difference in slopes between
the two groups. It is not testing whether either slope is different
from zero. In this case, a slope not different from zero indi-
cates no drug-suppression effect. Since the primary question of
interest in the current study was whether one or both of the
food-addiction groups displayed a suppression effect – not simply
whether they differed from each other – a test of simple slopes was
carried out for each group, strictly acknowledging that the results
are investigational and preliminary. In the non-food-addiction
group, the decrease from the placebo to the methylphenidate
condition for appetite ratings and food cravings was statisti-
cally signiﬁcant in both instances (p < 0.0001: η2p = 0.260
and 0.1.86, respectively). In the food-addiction group, neither
comparison was statistically signiﬁcant (p = 0.257 and 0.198,
respectively).
There were no signiﬁcant differences betweenmen andwomen,
nor did they differ on their food cravings and appetite ratingswhen
they were taking the placebo or the drug.
For the percentage of consumed snack-food, there was a statisti-
cally signiﬁcant interaction between Diagnostic Group and Days
(see Table 1). As indicated in Figure 3, and according to post hoc
comparisons, the food-addiction group showed no reduction in
Table 1 | Summary statistics for the within subject contrasts for the
2 [Days] × 2 [Sex] × 2 [Diagnostic Group] ANOVA with Food
Consumption as the dependent variable.
Source Type III SS df f p =
Days 1464.50 1 5.25 0.023
Days × Sex 833.22 1 2.99 0.086
Days × Diagnosis 1611.53 1 5.78 0.018
Days × Sex × Diagnosis 704.36 1 2.53 0.114
Error (Days) 36512.17 131 – –
FIGURE 3 | Plot for the Diagnostic Group × Days interaction with
percentage of snack-food consumption as the dependent variable.
FIGURE 4 | Plot for the Sex main effect with percentage of snack-food
consumption as the dependent variable.
food-intake in the drug condition from the placebo condition,
while there was a signiﬁcant decrease in the non-food-addiction
group (p < 0.0001: η2p = 0.276). There was also a signiﬁcant
main effect for Sex (p = 0.022: η2p = 0.039) with men con-
suming a greater percentage of their snack than women (see
Figure 4)4.
MOOD RATINGS
In light of the food consumption group differences in response
to methylphenidate, it was decided to assess whether this ﬁnding
reﬂected variation in subjective mood response to the drug, pos-
sibly as a result of differences in uptake or metabolism. The ﬁrst
item on the visual-analog scale, which was given every 15 min
after ingestion of the capsule, asked participants whether they felt
any mood or emotional changes that could be attributed to tak-
ing a stimulant medication. Participants indicated their response
by making a pencil mark on a line 147 mm long, where the left
4As a post hoc analysis, we investigated whether the methylphenidate effect on food-
intake was associated with its effect on food cravings and appetite ratings. We
calculated a difference score (placebo – drug) for each of the three food-related
variables and examined their bivariate inter-correlations. The food consumption
difference score was moderately correlated with the cravings and appetite difference
scores (r = 0.39 p < 0.0001, and r = 0.35 p < 0.0001, respectively), which were
themselves highly correlated (r = 0.76, p < 0.0001).
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FIGURE 5 | Plot for the Diagnostic Group ×Time Interval relationship
with mood ratings on the drug day as the dependent variable.
end of the line indicated “no effect” and the right end of the line
meant a “very strong” effect. Scores therefore varied between 0
and 147.
Repeated measure ANOVA was employed to assess the rating
at time periods: 30, 45, 60, 75, and 90 min after ingestion of the
capsule on the drug day. Similar to the previous analyses, between-
subjects factors were Sex and Diagnostic Group. Results indicated
a signiﬁcant effect across time periods (p < 0.0001: η2p = 0.254)
with a linear increase which stabilized at 75 min post ingestion.
There were, however, no differences between the food-addiction
and the control groups, nor a difference betweenmen andwomen.
Therewas alsono interactionbetween these twovariables. Figure 5
depicts the Time effect with separate lines for the food-addiction
and the non-food-addiction groups. It is noteworthy that the peak
subjective effect of the drug occurred at approximately 75 min
after the capsule was taken – the time the snack-food challenge
took place – after which the effect appeared to plateau in both
groups.
DISCUSSION
This study represents the ﬁrst empirical support for the food-
addiction theory, based on actual food intake. Results demon-
strated signiﬁcant eating-related differences in response to a
snack-food challenge between those diagnosed with YFAS food
addiction and the non-diagnosed control group. The former
reported stronger food cravings and greater appetite ratings fol-
lowing a taste of their favorite snack, and these differences
remained stable in both the placebo and the methylphenidate
conditions. While there was an overall diminution in these self-
reports from placebo to drug, as was expected, this effect was
driven primarily by a decrease in the non-food-addiction group,
since there was no diminution among those with food addic-
tion. With respect to food consumption, there was a signiﬁcant
interaction between Diagnostic Group and Days, again showing a
substantial decrease in snack-food consumption in the non-food-
addiction group, while there was no change in the food-addiction
group.
Interestingly, and contrary to prediction, there was no dif-
ference between the food-addiction and the non-food-addiction
groups in the percentage of food consumed in the placebo con-
dition. Since appetite ratings and food cravings were both higher
in the food-addiction group after the snack food was presented,
it is difﬁcult to explain why their food intake was also not greater
on the drug-free testing day. One possibility is that a ceiling effect
accounted for the null ﬁnding. Speciﬁcally, each participant was
given a single snack item such as a chocolate bar, a cookie, or a
small bag of chips. When analyzing the data, it was noted that a
large proportion of the sample consumed the entire snack in the
placebo condition – viz. 55%of the food-addiction group and44%
of the controls, compared to 45 and 25% respectively in the drug
condition. If the size of the snack had been larger, thereby provid-
ing an opportunity for greater variability at the high-consumption
end of the distribution, it is possible that placebo group differences
may have emerged.
To summarize, in response to the methylphenidate chal-
lenge, the food-addiction group appeared resistant to the typical
appetite-suppression effects of this drug. One can only specu-
late on themechanisms underlying these results. Methylphenidate
is lipophilic and therefore some of the drug may be sequestered
in fat tissue. However, since the mean BMI values were equiv-
alent in the two groups, differences in fat mass are unlikely to
account for the observed group effects. In addition, the absence
of any difference between the groups in the reporting of sub-
jective drug effects, or on the timing of the peak subjective
effects (see Figure 5), suggests that metabolic variation is unlikely
to account for the appetite/eating group differences. Because
methylphenidate’s mechanism of action is very similar to that of
cocaine – both block the DAT – some biological insights may
be gleaned from preclinical research using a strain of cocaine-
insensitive mice. The DAT-CI is a knock-in mouse line containing
three point mutations in the DAT gene. This genetic alteration
reduces DAT function and thereby leads to a hyper-dopaminergic
state as reﬂected by heightened spontaneous locomotion in these
animals compared to wild-type strains (O’Neill and Gu, 2013).
Since inhibition of the DAT is necessary for a response to cocaine,
as expected these genetically modiﬁed animals also do not display
an increase in locomotion following cocaine administration, nor
a conditioned place preference (O’Neill et al., 2013).
It is relevant that in previous human research we found evi-
dence of an increased striatal dopamine signal – as indexed by a
multi-locus genetic proﬁle – in a group of adults diagnosed with
YFAS food addiction compared to their age- and weight-matched
counterparts (Davis et al.,2013). Theseﬁndings are consistentwith
behavioral evidence that hyper-responsive brain reward mecha-
nisms may serve as a risk factor for the tendency to over-consume
highly palatable foods. Like the DAT-CI mice, individuals with
a predisposition to elevated dopamine activity may also be rela-
tively inured to the typical effects of stimulant drugs like cocaine
and methylphenidate. Our results may therefore have potential
clinical implications becausemethylphenidate is the ﬁrst-line drug
treatment for adults withADHD, and similar stimulant drugs have
recently shown some efﬁcacy in reducing binge episodes in adults
with BED (Shaffer, 2012; Gasior et al., 2013). Moreover, in light
of the evidence that food addiction may reﬂect a more severe
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form of BED (Davis, 2013), the results of this study could assist
in the development of personalized treatment management for
patients with compulsive overeating. Indeed, many patients who
use stimulant drugs therapeutically are non-responsive or discon-
tinue treatment because of negative side effects – ﬁndings which
suggest that pharmacogenetic research is needed to better under-
stand the factors that inﬂuence drug effectiveness and toxicity.
Regrettably, few adult studies have been conducted in this ﬁeld,
although some positive ﬁndings have identiﬁed inﬂuential mark-
ers on the DAT1 gene in relation to drug responsiveness (Contini
et al., 2013).
With respect to sex differences, we found little support
for our prediction that females would be more responsive
to methylphenidate than males. Considering there were no
Sex × Days interactions, our results do not mesh well with
pre-clinical research demonstrating a stronger response to
methylphenidate in females compared tomales. For example, ado-
lescent female rats showed a more robust sensitization to a dose
of methylphenidate compared to their male counterparts (Brown
et al., 2012), although later research found no sex differences
in conditioned-place preference using the same drug (Cummins
et al., 2013). It is also noteworthy that these drug effects weremod-
erated by the strain of rats and by the drug dose (Chelaru et al.,
2012).
Overall, the present study has added to the growing body
of research supporting the validity of the food-addiction con-
struct. To the best of our knowledge, this is the ﬁrst study
to use a well-controlled, laboratory-based, food challenge to
make eating-related comparisons between adults with and with-
out YFAS-diagnosed food addiction. In accord with our previous
evidence of strong links between food addiction and trait-like food
cravings (Davis et al., 2011), the current study also found elevated
state-related food cravings in response to the physical presence of a
highly palatable snack, which participants were asked to taste and
invited to eat. Nevertheless, it is important to emphasize that repli-
cation is needed with larger samples of individuals meeting YFAS
criteria for food addiction in order to improve conﬁdence in the
outcomes of this research. In the present study, the sample lacked
adequate power to test the Sex×DiagnosticGroup interaction due
to small frequencies in some of the cells. Future researchers are also
encouraged to provide a greater quantity in the snack-food chal-
lenge in order to increase the range of food-consumption scores.
In addition, larger samples will allow researchers to take account
of menstrual-cycle status in female participants since estrogen and
progesterone levels are known to inﬂuence response to stimulant
drugs (Evans and Foltin, 2010). And ﬁnally, we encourage studies
going forward to search for mechanisms to explain the apparent
food-related insensitivity to methylphenidate in those with YFAS
food addiction by using sophisticated brain imaging techniques.
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